• Publications
  • Influence
CD74 Is Expressed by Multiple Myeloma and Is a Promising Target for Therapy
TLDR
CD74 expression is frequent in multiple myeloma, with predominant expression by the malignant plasma cells, and LL1 mAb is well suited as a carrier of radionuclides, drugs, or toxins, and also has activity as an unlabeled mAb, thereby supporting its development for this unmet need in cancer therapy.
Fractionated radioimmunotherapy with 90Y‐clivatuzumab tetraxetan and low‐dose gemcitabine is active in advanced pancreatic cancer
TLDR
It has been demonstrated that the humanized clivatuzumab tetraxetan (hPAM4) antibody targets pancreatic ductal carcinoma selectively and fractionated radioimmunotherapy combined with low‐dose gemcitabine in this disease is studied.
Sphingolipid targets in cancer therapy
TLDR
The sphingolipid biosynthetic pathway, as it relates to the identification of important targets for drug discovery, and the development of novel agents capable of enhancing chemotherapy, is summarized.
PAM4-Reactive MUC1 Is a Biomarker for Early Pancreatic Adenocarcinoma
TLDR
The results suggest that expression of the PAM4-reactive antigen may represent an early event in the development of invasive pancreatic adenocarcinoma, and is unrelated to the VNTR peptide core epitopes of MUC1.
Treatment of Advanced Pancreatic Carcinoma with 90Y-Clivatuzumab Tetraxetan: A Phase I Single-Dose Escalation Trial
TLDR
90Y-Clivatuzumab tetraxetan was well tolerated with manageable hematologic toxicity at the maximal tolerated 90Y dose, and is a potential new therapeutic for advanced pancreatic cancer.
Horizontal transmission and retention of malignancy, as well as functional human genes, after spontaneous fusion of human glioblastoma and hamster host cells in vivo
TLDR
The spontaneous fusion of a human glioblastoma with normal hamster cells after xenogeneic transplantation is described, resulting in malignant cells that express both human and hamster genes and gene products, and retention of gliOBlastoma traits with an enhanced ability to metastasize.
Characterization of monoclonal antibody PAM4 reactive with a pancreatic cancer mucin
TLDR
The high specificity and intense reactivity of PAM4 with pancreatic carcinoma tissue suggests that the antibody may prove useful for in vitro diagnostic assays as well as in vivo targeting of diagnostic and therapeutic agents.
New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis.
TLDR
High sensitivity and specificity observed suggest that the PAM4-based immunoassay of circulating MUC1 may be useful in the diagnosis of pancreatic cancer.
Synergistic Interaction between Sphingomyelin and Gemcitabine Potentiates Ceramide-Mediated Apoptosis in Pancreatic Cancer
TLDR
It is indicated that the addition of SM can yield increased production of ceramide, mitochondrial depolarization, apoptosis, and cell death and addition of this lipid to agents that induce apoptosis may prove useful to enhance apoptosis and increase cytotoxicity in cancer cells.
Milatuzumab–SN-38 Conjugates for the Treatment of CD74+ Cancers
TLDR
CD74 is a suitable target for ADCs in some solid tumor xenografts, with efficacy largely influenced by uniformity of CD74 expression and with SN-38 conjugates providing the best therapeutic responses; SN-37 conjugate were preferable in solid cancers, whereas doxorubicin ADC was better in lymphoma tested.
...
1
2
3
4
5
...